Elzonris for Blastic Plasmacytoid Dendritic Cell Neoplasm

News
Article

Elzonris Product Image

ELZONRIS (tagraxofusp-erzs, Stemline® Therapeutics)

Indications: Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older

Dosage: Intravenously at 2mcg/kg over 15 mins once daily on days 1 & 5 of a 21-day cycle

  • First cycle recommended in inpatient setting, subsequent cycles either inpatient or other appropriate outpatient setting

Contraindications: None

Click here for more prescribing information

Recent Videos
Related Content
FDA Approves Tirzepatide for Obstructive Sleep Apnea in Patients with Obesity

FDA Approves Tirzepatide for Obstructive Sleep Apnea in Patients with Obesity

Killian Meara
December 20th 2024
Article

Zepbound from Eli Lilly is the first and only prescription medicine approved by the FDA for adults with obstructive sleep apnea and obesity.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff
August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

Tapinarof Cream 1% Approved by FDA to Treat Atopic Dermatitis in Adults, Children 2 Years and Older

Tapinarof Cream 1% Approved by FDA to Treat Atopic Dermatitis in Adults, Children 2 Years and Older

Killian Meara
December 16th 2024
Article

Vtama from Organon was previously approved in May 2022 to treat plaque psoriasis in adults.

FDA Roundup: ATX101 Gains Breakthrough Therapy Designation, Stelara Biosimilar Approval

FDA Roundup: ATX101 Gains Breakthrough Therapy Designation, Stelara Biosimilar Approval

Killian Meara
December 6th 2024
Article

Catch up on important FDA news from the week of December 2.

FDA Approves Acoramidis for ATTR-CM

FDA Approves Acoramidis for ATTR-CM

Lauren Biscaldi, MS, Managing Editor
November 25th 2024
Article

This approval marks the availability of the first near-complete stabilizer of transthyretin.

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

Killian Meara
November 12th 2024
Article

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

© 2024 MJH Life Sciences

All rights reserved.